10-Q: Aethlon Medical Reports Q3 2026 Results, Advances Hemopurifier Trial

Aethlon Medical, Inc. reported its Q3 2026 financial results, highlighting progress in its Australian oncology trial and a recent capital raise, while facing ongoing liquidity concerns.

Summary

• Net loss for the three months ended December 31, 2025, increased to $2,018,245 from $1,754,783 in the prior year.
• Net loss for the nine months ended December 31, 2025, improved to $5,267,203 from $7,133,196 in the prior year.
• Operating expenses for the three months ended December 31, 2025, increased by 13.6% to $2,062,116.
• Operating expenses for the nine months ended December 31, 2025, decreased by 26.9% to $5,364,335.
• Cash and cash equivalents increased to $6,956,397 at December 31, 2025, from $5,501,261 at March 31, 2025.
• Working capital increased to $5,884,382 at December 31, 2025, from $4,050,514 at March 31, 2025.
• Completed Cohort 1 of the Australian oncology trial with no safety concerns and began enrollment for Cohort 2.
• Canceled the planned Indian clinical trial to conserve resources and focus on the Australian trial.
• Successfully raised approximately $3.3 million gross proceeds from a private placement (PIPE Offering) and warrant inducement in December 2025.
• Implemented a 1-for-10 reverse stock split on October 16, 2025, and a 1-for-8 reverse stock split on June 9, 2025, to regain Nasdaq compliance.
• Received an Australian R&D tax incentive payment of US $218,314 in October 2025.
• Management expects existing cash as of December 31, 2025, not to be sufficient to fund operations for at least twelve months, indicating substantial doubt about the company's ability to continue as a going concern.

Sentiment

Score: 3

Explanation: StockSavvy.ai views this as a highly speculative filing. While there's progress in clinical trials and a recent capital raise, the explicit "going concern" warning, continued net losses, and reliance on further capital raises indicate significant financial instability and high risk.

Positives

• Net loss for the nine months ended December 31, 2025, significantly improved to $5.27 million from $7.13 million in the prior year.
• Operating expenses for the nine months ended December 31, 2025, decreased by 26.9% ($1.97 million) compared to the prior year.
• Cash and cash equivalents increased to $6.96 million at December 31, 2025, from $5.50 million at March 31, 2025.
• Working capital increased to $5.88 million at December 31, 2025, from $4.05 million at March 31, 2025.
• Successfully completed Cohort 1 of the Australian oncology trial with no reported serious adverse events (SAEs) or Dose-Limiting Toxicities (DLTs), and the Data Safety Monitoring Board (DSMB) recommended proceeding to Cohort 2.
• Received Breakthrough Device designation from the FDA for two independent indications for the Hemopurifier (advanced cancer and life-threatening viral infections).
• Successfully raised approximately $3.3 million in gross proceeds from a private placement and warrant inducement in December 2025.
• Received a US $218,314 Australian R&D tax incentive payment in October 2025, reducing R&D expense.
• Pre-clinical studies demonstrated >98% removal of platelet-derived EVs from healthy human plasma by the Hemopurifier.
• Maintains an open Investigational Device Exemption (IDE) for viral indications, preserving the ability to respond to future outbreaks.

Negatives

• Net loss for the three months ended December 31, 2025, increased to $2.02 million from $1.75 million in the prior year.
• Operating expenses for the three months ended December 31, 2025, increased by 13.6% ($247,000) compared to the prior year, primarily due to higher payroll.
• Management expects existing cash not to be sufficient to fund operations for at least twelve months, raising substantial doubt about the company's ability to continue as a going concern.
• The company canceled its planned clinical trial in India to conserve resources, indicating financial constraints.
• COVID-19 clinical trials in the U.S. and India were terminated due to low ICU enrollment.
• The company implemented two reverse stock splits (1-for-8 in June 2025 and 1-for-10 in October 2025) to maintain Nasdaq listing compliance due to minimum bid price requirements.
• Outstanding stock options had no intrinsic value as of December 31, 2025, with the closing share price of $2.77 per share being below the exercise price.
• The company continues to incur increasing negative cash flows and net losses for the foreseeable future.

Risks

• Substantial doubt exists about the company's ability to continue as a going concern due to insufficient cash to fund operations for at least twelve months.
• Inability to raise additional capital on acceptable terms, or at all, which could force the company to significantly curtail or cease operations, including research and development programs and clinical trials.
• Uncertainty regarding the timing and results of future clinical trials, and the successful completion of trials.
• Uncertainty of FDA approval of product candidates and approval in foreign countries; some patents may expire before regulatory approval is obtained.
• Uncertainty of market acceptance for the Hemopurifier.
• Competition from other providers and products.
• Inherent risks in product development.
• Ability to protect intellectual property rights.
• Changes in government regulation and compliance obligations.
• Impact of inflation, recent bank failures, and ongoing military conflicts (Russia-Ukraine, Israel) on capital markets, the U.S. economy, timelines, and access to capital.
• Inadequate funding for the FDA, USPTO, and other government agencies could hinder their ability to review and approve products, process regulatory submissions, and impact access to public markets for capital.
• Still awaiting FDA approval of a separate supplement to qualify an additional key component supplier for manufacturing.

Future Outlook

Management expects existing cash as of December 31, 2025, not to be sufficient to fund operations for at least twelve months from the issuance date of the financial statements, raising substantial doubt about the company's ability to continue as a going concern. The company is actively evaluating strategic and financing options, including potential equity offerings, to extend its cash runway. Future capital requirements will depend on progress with pre-clinical testing and clinical trials, the number and breadth of clinical programs, intellectual property costs, regulatory obligations, and the competitive landscape. The company expects to continue incurring increasing negative cash flows and net losses for the foreseeable future and plans to access equity markets for additional capital, though there is no assurance of favorable terms or availability. Clinical trial expenses for the Australian oncology trial are expected to increase, including manufacturing costs for additional Hemopurifiers, and rent payments are also projected to rise. The company expects to continue enrollment and treatment of additional patients in Cohort 2 of the Australian oncology trial.

Management Comments

• "We are actively evaluating a range of strategic and financing options to extend our cash runway and support our ongoing operations, including clinical development activities."
• "If we are unable to raise additional capital when needed, we may be forced to significantly curtail or cease operations, including research and development programs and clinical trials."
• "We believe that certain patent applications and/or other patents issued to us more recently will help protect the proprietary nature of our Hemopurifier treatment technology."
• "Given the level of uncertainty regarding the duration and impact of these events on capital markets and the U.S. economy, we are unable to assess the impact on our timelines and future access to capital."

Industry Context

StockSavvy.ai notes that Aethlon Medical operates in the highly capital-intensive and regulated medical therapeutic device sector, where long development cycles and significant R&D investment are standard. The FDA Breakthrough Device designation is a positive signal, potentially accelerating market access, but the company's ongoing liquidity challenges and reliance on capital raises are common for clinical-stage biotech firms, contrasting with more established players with revenue streams. The termination of the India trial and COVID-19 trials due to resource constraints and low enrollment, respectively, highlight the operational challenges and strategic prioritization required in this competitive landscape.

Comparison to Industry Standards

• The company's net loss and negative cash flow from operations are typical for a clinical-stage medical device company that has not yet commercialized a product.
• The FDA Breakthrough Device designation is a significant achievement, placing the Hemopurifier in a category with devices like Medtronic's MiniMed 780G system or Abbott's FreeStyle Libre, which received similar designations for their potential to provide more effective treatment for life-threatening conditions.
• The need for multiple reverse stock splits to maintain Nasdaq listing is a red flag, often seen in smaller, speculative biotech companies struggling with market valuation, unlike larger, stable pharmaceutical companies.
• The successful completion of Cohort 1 of the Australian oncology trial with no SAEs or DLTs is a positive safety indicator, comparable to early-stage trial results from peers like Kura Oncology or Mirati Therapeutics in their initial safety assessments for novel cancer therapies.
• The reliance on equity financing and the "going concern" warning are common for pre-revenue biotech firms, but the frequency of capital raises and the explicit doubt about liquidity underscore a higher risk profile compared to well-funded peers or those with diversified pipelines.

Corporate Governance

Related Party Transactions

• Accrued board fees owed to non-employee directors totaled $68,250 as of December 31, 2025.
• Paid $68,250 in board fees to non-employee directors during the three months ended December 31, 2025, and an aggregate of $204,750 during the nine months ended December 31, 2025.
• Accrued separation expenses owed to former executive officers were $0 as of December 31, 2025, after paying $346,286 during the nine months ended December 31, 2025.
• Accrued vacation balances owed to current employees totaled $169,596 as of December 31, 2025.

Stakeholder Impact

• Shareholders face dilution risk from future equity offerings and warrant exercises, and potential for significant share price volatility due to the "going concern" warning and reverse stock splits. Positive impact from clinical trial progress and FDA Breakthrough Device designation.
• Employees' continued employment is dependent on securing additional capital. Accrued vacation balances are a liability.
• Future customers may benefit from new therapeutic options if the Hemopurifier gains regulatory approval.
• Creditors face increased risk associated with the "going concern" warning.
• Regulatory bodies are engaged in ongoing review processes for approvals and compliance.

Next Steps

• Continue enrollment and treatment of additional patients in Cohort 2 of the Australian oncology trial.
• Evaluate a range of strategic and financing options, including potential equity offerings, to extend cash runway.
• Work with the FDA to qualify an additional key component supplier for manufacturing.
• Seek stockholder approval for the issuance and exercisability of certain warrants from the December 2025 PIPE Offering.
• Maintain effectiveness of the registration statement for resale of shares underlying warrants.
• Continue exploring potential new applications for the Hemopurifier through internal pre-clinical research and academic collaborations.

Key Dates

Recommendation

Despite some positive clinical trial progress and a recent capital raise, the explicit "substantial doubt about the Company's ability to continue as a going concern" is a critical red flag for investors. The company's ongoing significant net losses, negative cash flow from operations, and continuous need for additional capital raises (which often lead to dilution) present an extremely high-risk investment profile. The repeated reverse stock splits to maintain Nasdaq listing further underscore underlying financial and market valuation challenges. A seasoned investor would likely view the fundamental financial instability as outweighing the early-stage clinical advancements, recommending a sell to avoid potential significant capital loss.

Keywords

Aethlon Medical, Hemopurifier, oncology trial, cancer treatment, viral infections, medical device, FDA Breakthrough Device, clinical trials, extracellular vesicles, capital raise, 10-Q, financial results, Nasdaq compliance, reverse stock split, R&D tax incentive, liquidity, going concern